0001193125-26-177317.txt : 20260424 0001193125-26-177317.hdr.sgml : 20260424 20260424161716 ACCESSION NUMBER: 0001193125-26-177317 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20260420 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260424 DATE AS OF CHANGE: 20260424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 26894293 BUSINESS ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 8-K/A 1 d104779d8ka.htm 8-K/A 8-K/A
ANAPTYSBIO, INC true 0001370053 0001370053 2026-04-20 2026-04-20
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

(Amendment No. 1)

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2026

 

 

ANAPTYSBIO, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37985   20-3828755
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

10770 Wateridge Circle, Suite 210, San Diego, CA   92121
(Address of principal executive offices)   (Zip Code)

(858) 362-6295

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
symbol(s)

  

Name of each exchange
on which registered

Common stock, par value $0.001 per share   ANAB   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Explanatory Note

On April 20, 2026 (the “Distribution Date”) at 12:01 a.m., New York City time, AnaptysBio, Inc. (the “Company”) completed the previously announced separation (the “Spin-Off”) of First Tracks Biotherapeutics, Inc. (“First Tracks Biotherapeutics”) from the Company. The Spin-Off of First Tracks Biotherapeutics was achieved through the Company’s pro rata distribution of all of the outstanding shares of common stock of First Tracks Biotherapeutics to holders of record of the Company’s common stock. Each holder of record of the Company’s common stock received one share of First Tracks Biotherapeutics’ common stock for every one share of Company common stock held on April 6, 2026, the record date for the distribution. On April 20, 2026, First Tracks Biotherapeutics’ shares of common stock began trading on the Nasdaq Stock Market LLC under the ticker symbol “TRAX.”

In this Amendment No. 1 the Company amends the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 20, 2026 (the “Original Form 8-K”) that reported the completion of the Spin-Off. The Original Form 8-K did not include the unaudited pro forma financial information of the Company reflecting the performance of the Company’s businesses after giving effect to the Spin-Off. This Amendment No. 1 to the Original Form 8-K is being filed to include such pro forma financial information as required under Item 9.01(b) of Form 8-K.

Unaudited pro forma financial information included in this Amendment No. 1 to the Original Form 8-K has been presented to illustrate the estimated effects of the Spin-Off and is not necessarily indicative of the results of operations that the Company would have achieved had the Spin-Off been completed as of the dates indicated or of the results that may be obtained in the future.

 

Item 9.01

Financial Statements and Exhibits.

 

  (b)

Pro Forma Financial Information

The following unaudited pro forma financial information of the Company is filed as Exhibit 99.1 to this Amendment No. 1 to the Original Form 8-K and is incorporated herein by reference.

 

  •  

Unaudited Pro Forma Condensed Consolidated Balance Sheet as of December 31, 2025

 

  •  

Unaudited Pro Forma Condensed Consolidated Statements of Operations for each of the three years ended December 31, 2025, 2024 and 2023

 

  •  

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements.

 

  (d)

Exhibits

 

Exhibit No.

   

Description

99.1    Unaudited Pro Forma Consolidated Financial Information of AnaptysBio, Inc.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 24, 2026

 

ANAPTYSBIO, INC.
By:  

/s/ Dan Faga

  Dan Faga
  President and Chief Executive Officer
 EX-99.1 2 d104779dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

Spin-Off of First Tracks Biotherapeutics

On April 20, 2026 (the “Distribution Date”), AnaptysBio, Inc. (the “Company” or “AnaptysBio”) completed the separation of its biopharma operations by means of a spin-off (the “Spin-Off”) into a new, independent public company, First Tracks Biotherapeutics, Inc. (“First Tracks”).

Unaudited Pro Forma Condensed Consolidated Financial Information

The following unaudited pro forma condensed consolidated financial statements as of and for the year ended December 31, 2025, and for each of the years ended December 31, 2024, and 2023, reflect adjustments to the Company’s historical financial results related to the:

 

  •  

Spin-Off and related events. The unaudited pro forma condensed consolidated statement of operations for the year ended December 31, 2025 gives effect to the Spin-Off and related events as if they occurred on January 1, 2025. The unaudited pro forma condensed consolidated balance sheet as of December 31, 2025 gives effect to the Spin-Off and related events as if they occurred on December 31, 2025, the Company’s latest balance sheet date.

 

  •  

First Tracks Discontinued Operations. The unaudited pro forma condensed consolidated financial statements reflect the reclassification of First Tracks as Discontinued Operations for all periods presented.

The unaudited pro forma condensed consolidated financial statements were prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma condensed consolidated financial statements (i) are presented based on information currently available, (ii) are intended for informational purposes only, (iii) are not necessarily indicative of and do not purport to represent what the Company’s operating results would have been had the Spin-Off and related events occurred as described or what the Company’s future operating results will be after giving effect to these events, and (iv) do not reflect all actions that may be undertaken by the Company after the Spin-Off.

The unaudited pro forma condensed consolidated financial statements and the accompanying notes should be read together with:

 

  •  

The audited consolidated financial statements, the accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations of AnaptysBio as of and for the year ended December 31, 2025 in AnaptysBio’s Annual Report on Form10-K for the year ended December 31, 2025.

 

  •  

First Tracks audited annual combined financial statements, the accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in First Track’s Registration Statement on Form 10 filed with the SEC on March 3, 2026 and most recently amended on March 27, 2026.

In the enclosed unaudited pro forma condensed consolidated statements of operations and unaudited pro forma condensed consolidated balance sheet, the amounts reflected in the columns presented are described below:

Historical AnaptysBio, Inc.

This column reflects the Company’s historical financial statements for the periods presented and does not reflect any adjustments related to the Spin-Off and related events.

The historical consolidated statements of operations for each of the years ended December 31, 2025, 2024 and 2023 were derived from the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2025.

First Tracks Discontinued Operations

The unaudited pro forma financial information related to First Tracks Discontinued Operations has been prepared in accordance with the discontinued operations guidance in Accounting Standards Codification 205, “Financial Statement Presentation” (“ASC 205”) and therefore does not reflect what AnaptysBio or First Tracks’s results of operations would have been on a stand-alone basis, and are not necessarily indicative of AnaptysBio or First Tracks’s future results of operations.

Transaction Accounting Adjustments

The unaudited pro forma condensed consolidated financial statements as of and for the year ended December 31, 2025 reflect additional pro forma adjustments.

AnaptysBio, Inc,

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF DECEMBER 31, 2025

(in thousands, except par value)

 

     Historical
AnaptysBio,
Inc.		     First Tracks
Biotherapeutics,
Inc.
Discontinued
Operations
(A)		     Transaction
Accounting
Adjustments		     Pro Forma
AnaptysBio,
Inc.
Continuing
Operations		  

ASSETS

         

Current assets:

         

Cash and cash equivalents

    $ 238,196     $ —      $ (100,000 ) (B)    $ 138,196  

Receivables from collaborative partners

      33,850       —        —        33,850  

Short-term investments

      73,442       —        —        73,442  

Prepaid expenses and other current assets

      4,762       (4,762 )      —        —   
  

 

 

    

 

 

    

 

 

    

 

 

  

Total current assets

      350,250       (4,762 )      (100,000 )      245,488  

Property and equipment, net

      1,370       (1,370 )      —        —   

Operating lease right-of-use assets

      12,519       —        —        12,519  

Other long-term assets

      256       —        —        256  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total assets

    $ 364,395     $ (6,132 )    $ (100,000 )    $ 258,263  
  

 

 

    

 

 

    

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY

         

Current liabilities:

         

Accounts payable

    $ 3,871     $ —      $ —      $ 3,871  

Accrued expenses

      32,674       —        47,354  (C)(D)(E)      80,028  

Current portion of operating lease liability

      2,080       —        —        2,080  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total current liabilities

      38,625       —        47,354       85,979  

Liability related to sale of future royalties

      276,528       —        —        276,528  

Operating lease liability, net of current portion

      12,032       —        —        12,032  

Stockholders’ equity:

         

Common stock

      28       —        —        28  

Additional paid in capital

      809,765       —        —        809,765  

Accumulated other comprehensive loss

      (24 )      —        —        (24 ) 

Accumulated deficit

      (772,559 )      (6,132 )      (147,354 ) (B)(C)(D)(E)      (926,045 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Total stockholders’ equity

      37,210       (6,132 )      (147,354 )      (116,276 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 364,395     $ (6,132 )    $ (100,000 )    $ 258,263  
  

 

 

    

 

 

    

 

 

    

 

 

  

AnaptysBio, Inc.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2025

(in thousands, except per share amounts)

 

     Historical
AnaptysBio,
Inc.		     First Tracks
Biotherapeutics, Inc.
Discontinued
Operations
(A)		     Transaction
Accounting
Adjustments		     Pro Forma
AnaptysBio, Inc.
Continuing
Operations		  

Collaboration revenue

    $ 234,603     $ —      $ —      $ 234,603  
  

 

 

    

 

 

    

 

 

    

 

 

  

Operating expenses:

         

Research and development

      135,970       (139,614 )      —        (3,644 ) 

General and administrative

      50,737       (39,392 )      9,014  (C)(D)      20,359  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      186,707       (179,006 )      9,014       16,715  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income from operations

      47,896       179,006       (9,014 )      217,888  
  

 

 

    

 

 

    

 

 

    

 

 

  

Other (expense) income, net:

         

Interest income

      13,499       (3,586 )      —        9,913  

Non-cash interest expense for the sale of future royalties

      (79,893 )      —        —        (79,893 ) 

Other income, net

      5,430       23       —        5,453  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total other expense, net

      (60,964 )      (3,563 )      —        (64,527 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

(Loss) income before income taxes

      (13,068 )      175,443       (9,014 )      153,361  

Provision for income taxes

      (164 )      —        (38,340 ) (E)      (38,504 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net (loss) Income

      (13,232 )      175,443       (47,354 )      114,857  
  

 

 

    

 

 

    

 

 

    

 

 

  

Other comprehensive loss:

         

Unrealized loss on available for sale securities

      (329 )      —        —        (329 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Comprehensive (loss) income

    $ (13,561 )    $ 175,443     $ (47,354 )    $ 114,528  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net (loss) income per common share:

         

Basic

    $ (0.46 )        $ 3.99  
  

 

 

        

 

 

  

Diluted

    $ (0.46 )        $ 3.07  
  

 

 

        

 

 

  

Weighted-average number of shares outstanding:

         

Basic

      28,758           28,758  
  

 

 

        

 

 

  

Diluted

      28,758           37,453  
  

 

 

        

 

 

  

AnaptysBio, Inc.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2024

(in thousands, except per share amounts)

 

     Historical
AnaptysBio, Inc		     First Tracks
Biotherapeutics,
Inc. Discontinued
Operations
(A)		     Pro Forma
AnaptysBio, Inc.
Continuing
Operations		  

Collaboration revenue

    $ 91,280     $ —      $ 91,280  
  

 

 

    

 

 

    

 

 

  

Operating expenses:

       

Research and development

      163,840       (152,345 )      11,495  

General and administrative

      42,389       (28,756 )      13,633  
  

 

 

    

 

 

    

 

 

  

Total operating expenses

      206,229       (181,101 )      25,128  
  

 

 

    

 

 

    

 

 

  

(Loss) income from operations

      (114,949 )      181,101       66,152  
  

 

 

    

 

 

    

 

 

  

Other (expense) income, net:

       

Interest income

      19,794       (17,382 )      2,412  

Non-cash interest expense for the sale of future royalties

      (50,087 )      —        (50,087 ) 

Other income, net

      14       (14 )      —   
  

 

 

    

 

 

    

 

 

  

Total other expense, net

      (30,279 )      (17,396 )      (47,675 ) 
  

 

 

    

 

 

    

 

 

  

(Loss) income before income taxes

      (145,228 )      163,705       18,477  

Provision for income taxes

      (3 )      —        (3 ) 
  

 

 

    

 

 

    

 

 

  

Net loss

      (145,231 )      163,705       18,474  
  

 

 

    

 

 

    

 

 

  

Other comprehensive (loss) income:

       

Unrealized gain on available for sale securities

      1,102       —        1,102  
  

 

 

    

 

 

    

 

 

  

Comprehensive (loss) income

    $ (144,129 )    $ 163,705     $ 19,576  
  

 

 

    

 

 

    

 

 

  

Net (loss) income per common share:

       

Basic

    $ (5.12 )      $ 0.65  
  

 

 

      

 

 

  

Diluted

    $ (5.12 )      $ 0.52  
  

 

 

      

 

 

  

Weighted-average number of shares outstanding:

       

Basic

      28,382         28,382  
  

 

 

      

 

 

  

Diluted

      28,382         35,298  
  

 

 

      

 

 

  

AnaptysBio, Inc.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2023

(in thousands, except per share amounts)

 

     Historical
AnaptysBio, Inc		     First Tracks
Biotherapeutics,
Inc. Discontinued
Operations
(A)		     Pro Forma
AnaptysBio, Inc.
Continuing
Operations		  

Collaboration revenue

    $ 17,157     $ —      $ 17,157  
  

 

 

    

 

 

    

 

 

  

Operating expenses:

       

Research and development

      132,283       (90,255 )      42,028  

General and administrative

      41,946       (20,867 )      21,079  

Acquired in-process research and development

      7,339       (7,339 )      —   
  

 

 

    

 

 

    

 

 

  

Total operating expenses

      181,568       (118,461 )      63,107  
  

 

 

    

 

 

    

 

 

  

Loss from operations

      (164,411 )      118,461       (45,950 ) 
  

 

 

    

 

 

    

 

 

  

Other income (expense), net:

       

Interest income

      18,873       (12,313 )      6,560  

Non-cash interest expense for the sale of future royalties

      (18,083 )      —        (18,083 ) 

Other expense, net

      (2 )      2       —   
  

 

 

    

 

 

    

 

 

  

Total other income (expense), net

      788       (12,311 )      (11,523 ) 
  

 

 

    

 

 

    

 

 

  

Loss before income taxes

      (163,623 )      106,150       (57,473 ) 

Benefit for income taxes

      4       0       4  
  

 

 

    

 

 

    

 

 

  

Net loss

      (163,619 )      106,150       (57,469 ) 
  

 

 

    

 

 

    

 

 

  

Other comprehensive loss:

       

Unrealized gain on available for sale securities

      4,449       —        4,449  
  

 

 

    

 

 

    

 

 

  

Comprehensive loss

    $ (159,170 )    $ 106,150     $ (53,020 ) 
  

 

 

    

 

 

    

 

 

  

Net loss per common share:

       

Basic and diluted

    $ (6.08 )      $ (2.13 ) 
  

 

 

      

 

 

  

Weighted-average number of shares outstanding:

       

Basic and diluted

      26,924         26,924  
  

 

 

      

 

 

  

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

First Tracks Biotherapeutics, Inc. Discontinued Operations:

(A) Reflects the discontinued operations of First Tracks Biotherapeutics, including the associated assets, liabilities, equity and results of operations in accordance with ASC 205.

Transaction Accounting Adjustments:

(B) Reflects an initial cash distribution of $100.0 million provided to First Tracks Biotherapeutics in connection with the Spin-Off.

(C) Subsequent to December 31, 2025, AnaptysBio anticipates it will incur additional non-recurring costs of approximately $7.0 million to complete the Spin-Off. These costs primarily relate to transaction advisory and professional fees associated with the Spin-Off and are expected to be incurred within 12 months of the Spin-Off.

(D) In connection with the Spin-Off, AnaptysBio and First Tracks Biotherapeutics entered into a transition services agreement on April 20, 2026 (the “Transition Services Agreement”), pursuant to which First Tracks Biotherapeutics will provide certain post-closing services to AnaptysBio on a transitional basis. As such, a pro forma adjustment of approximately $2.0 million has been recorded as an increase to selling, general and administrative expenses.

(E) Reflects income tax expense based on an estimated 25% combined federal and state tax rate on the net income from 2025 excluding impacts of available net operating losses and R&D credits.

EX-101.SCH 3 anab-20260420.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 anab-20260420_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Description Amendment Description EX-101.PRE 5 anab-20260420_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information
Apr. 20, 2026
Cover [Abstract]  
Entity Registrant Name ANAPTYSBIO, INC
Amendment Flag true
Entity Central Index Key 0001370053
Document Type 8-K/A
Document Period End Date Apr. 20, 2026
Entity Incorporation State Country Code DE
Entity File Number 001-37985
Entity Tax Identification Number 20-3828755
Entity Address, Address Line One 10770 Wateridge Circle
Entity Address, Address Line Two Suite 210
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 362-6295
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol ANAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Description In this Amendment No. 1 the Company amends the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 20, 2026 (the “Original Form 8-K”) that reported the completion of the Spin-Off. The Original Form 8-K did not include the unaudited pro forma financial information of the Company reflecting the performance of the Company’s businesses after giving effect to the Spin-Off. This Amendment No. 1 to the Original Form 8-K is being filed to include such pro forma financial information as required under Item 9.01(b) of Form 8-K.
XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports anab-20260420.xsd anab-20260420_lab.xml anab-20260420_pre.xml d104779d8ka.htm http://xbrl.sec.gov/dei/2025 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d104779d8ka.htm": { "nsprefix": "anab", "nsuri": "http://www.anaptysbio.com/20260420", "dts": { "schema": { "local": [ "anab-20260420.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "anab-20260420_lab.xml" ] }, "presentationLink": { "local": [ "anab-20260420_pre.xml" ] }, "inline": { "local": [ "d104779d8ka.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2025": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 24 }, "report": { "R1": { "role": "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2026-04-20_to_2026-04-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d104779d8ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2026-04-20_to_2026-04-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d104779d8ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "terseLabel": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://www.anaptysbio.com//20260420/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-26-177317-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-26-177317-xbrl.zip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end XML 16 d104779d8ka_htm.xml IDEA: XBRL DOCUMENT 0001370053 2026-04-20 2026-04-20 ANAPTYSBIO, INC true 0001370053 8-K/A 2026-04-20 DE 001-37985 20-3828755 10770 Wateridge Circle Suite 210 San Diego CA 92121 (858) 362-6295 false false false false Common stock, par value $0.001 per share ANAB NASDAQ false In this Amendment No. 1 the Company amends the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 20, 2026 (the “Original Form 8-K”) that reported the completion of the Spin-Off. The Original Form 8-K did not include the unaudited pro forma financial information of the Company reflecting the performance of the Company’s businesses after giving effect to the Spin-Off. This Amendment No. 1 to the Original Form 8-K is being filed to include such pro forma financial information as required under Item 9.01(b) of Form 8-K.